News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Pharma CEOs under scrutiny after Trump meeting Pharma leaders grilled by analysts after Trump meeting.
News Pharma CEOs to meet Trump today Pharma CEOs including Novartis’ Joe Jimenez are to meet Donald Trump this afternoon – following a turbulent start to his presidency and his attacks on the industry over pricing.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
News Novartis less exposed to US pricing pressure, says Jimenez Europe and Asia account for a large share of company's income.
News J&J to "price responsibly", says CEO post Trump meeting Gorsky promises "transparency report" on pricing.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
